drugset / Trial / NCT04596033
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
TiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune cells. First, Genocea confirms which cancer proteins are recognized already by each patient's T cells using ATLAS™. Then, immune cells that recognize these cancer proteins are multiplied many times (a process called PLANET™) to create a personalized GEN-011 cell therapy, which is given back to the patient in one or more intravenous (IV) infusions.
Timeline
- Start
- 2020-11-11
- Primary completion
- 2022-06-27
- Completion
- 2022-06-27
Outcome
Outcome not reported
Stopped (Business): “Business reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GEN-011 | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | IL-2 | Protein / enzyme biologic | — | — |